2018
DOI: 10.2188/jea.je20160149
|View full text |Cite
|
Sign up to set email alerts
|

Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002–2013)

Abstract: BackgroundThis study examined the annual prevalence of atrial fibrillation (AF) and its associated comorbidities, as well as the prevalence of warfarin therapy in South Korean patients with AF.MethodsThe National Health Insurance Service-National Sample Cohort database was searched for subjects aged ≥30 years diagnosed with AF from 2002–2013. The prevalence of AF was analyzed by sex and age, as was the current status of warfarin therapy in AF patients according to CHA2DS2-VASc score and comorbidities.ResultsTh… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
12
2

Year Published

2018
2018
2023
2023

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 17 publications
(15 citation statements)
references
References 42 publications
1
12
2
Order By: Relevance
“…However, OAC prescriptions do not routinely follow the guideline; even for patients with stroke and AF, the use of warfarin was only 20% in China 24. Compared with a previous study that reported an OAC therapy use of 2.5%–2.7% in a Chinese population,25 our study revealed a slight improvement in percentages of patients with AF on OAC therapy, but it remained significantly lower than those in Europe and North American as well as in other countries (67% in Europe, 50% in the USA, 75% in Japan, 30% in Cameroon and 39.1% in South Korea) 26. Therefore, a considerable number of patients of our AF population did not receive OAC therapy, indicating that adequate screening and education to promote the use of OAC therapy in patients with AF in northeast China should be highlighted.…”
Section: Discussioncontrasting
confidence: 74%
“…However, OAC prescriptions do not routinely follow the guideline; even for patients with stroke and AF, the use of warfarin was only 20% in China 24. Compared with a previous study that reported an OAC therapy use of 2.5%–2.7% in a Chinese population,25 our study revealed a slight improvement in percentages of patients with AF on OAC therapy, but it remained significantly lower than those in Europe and North American as well as in other countries (67% in Europe, 50% in the USA, 75% in Japan, 30% in Cameroon and 39.1% in South Korea) 26. Therefore, a considerable number of patients of our AF population did not receive OAC therapy, indicating that adequate screening and education to promote the use of OAC therapy in patients with AF in northeast China should be highlighted.…”
Section: Discussioncontrasting
confidence: 74%
“…Therefore, the prevalence of both AF and HF in Korea is expected to increase. 6 Indeed, data have shown that the prevalence of AF increased from 0.36% in 2003 to 0.89% in 2013, 26 and that the prevalence of HF is expected to increase from 1.53% in 2013 to 3.35% by 2040. 27 These results indicate that both AF and HF will represent a significant public health burden in the near future.…”
Section: Af and Hf In Koreamentioning
confidence: 99%
“…A trend study in Korea between 2000 to 2013 showed that 86.1% of patients with AF had CHA 2 DS 2 -VASc score ≥2, however, only 39.1% of these patients were taking warfarin. 87) In a recent national study of patients with AF from Korea (n=276,246), using the National Health Insurance Service database between 2008 to 2015, most of the patients had CHA 2 DS 2 -VASc score ≥2 (78.2% in 2008 and 83.2% in 2015). 88) In the whole study population, OAC use increased from 34.7% to 50.6% and NOAC use accounted for 50% of total OAC use.…”
Section: Current Situation Of Oral Anticoagulation Use In Asiamentioning
confidence: 99%